Key Takeaways
Semaglutide and tirzepatide are peptide-based receptor agonists studied extensively in metabolic research, but they work through different receptor pathways. Semaglutide primarily activates the glucagon-like peptide-1 receptor, or GLP-1R, while tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide receptors, or GIPR.
That distinction of single versus dual incretin receptor agonism is central to the semaglutide vs. tirzepatide comparison.
Researchers now have more than one separate clinical program to work from. Two randomized trials have directly compared the molecules in humans: SURPASS-2, conducted in adults with type 2 diabetes, and SURMOUNT-5, conducted in adults with obesity without type 2 diabetes. The 2025 SURMOUNT-5 trial is particularly useful because it directly evaluated tirzepatide against semaglutide over 72 weeks under the same study protocol.
Disclaimer: All products sold by ReNu Wellness Peptides are intended strictly for laboratory and scientific research purposes only and are not for human or veterinary use. The information provided in this article is for educational purposes only and should not be considered medical advice. These products are not intended to diagnose, treat, cure, or prevent any disease.
| Research Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Primary receptor activity | GLP-1 receptor agonist | GIP + GLP-1 receptor agonist |
| Receptors targeted | 1 | 2 |
| Research classification | GLP-1 analogue | Dual incretin receptor agonist |
| Development focus | Metabolic signaling, glucose regulation, obesity, cardiovascular outcomes and related areas | Metabolic signaling, glucose regulation, obesity, cardiovascular outcomes and related areas |
| Direct obesity comparison | Studied against tirzepatide in SURMOUNT-5 | Studied against semaglutide in SURMOUNT-5 |
| Direct type 2 diabetes comparison | Studied against tirzepatide in SURPASS-2 | Studied against semaglutide in SURPASS-2 |
| U.S. regulatory status | FDA-approved drug products containing semaglutide exist | FDA-approved drug products containing tirzepatide exist |
The important scientific difference is therefore receptor pharmacology, not simply that both compounds are frequently grouped under the broader GLP-1 category.
Semaglutide is a synthetic GLP-1 analogue designed to activate the GLP-1 receptor.
Its molecular development was described in a 2015 Journal of Medicinal Chemistry paper by Lau and colleagues. The researchers developed semaglutide as a long-acting GLP-1 analogue using structural modifications intended to increase metabolic stability and prolong its pharmacokinetic profile.
GLP-1 receptor signaling has several biological roles relevant to metabolic research, including effects on glucose-dependent insulin secretion, glucagon regulation, food intake, and gastrointestinal physiology.
Semaglutide’s receptor activity is relatively straightforward from a comparison standpoint:
Semaglutide → GLP-1 receptor
It does not rely on simultaneous GIP receptor agonism for its primary mechanism.
Tirzepatide, also known by its development code LY3298176, is a synthetic peptide with agonist activity at both GIP and GLP-1 receptors.
Early pharmacological research described LY3298176 as a fatty-acid-modified peptide engineered to activate both incretin receptor pathways. Cell and animal research demonstrated activity at GIPR and GLP-1R before the molecule progressed into large clinical research programs.
Its receptor profile can be summarized as:
Tirzepatide → GIP receptor + GLP-1 receptor
The mechanism is more nuanced than simply combining two equal receptor signals. Research published in Cell Metabolism found that tirzepatide displays greater engagement of the GIP receptor and distinct signaling behavior at the GLP-1 receptor, including biased signaling characteristics.
That makes tirzepatide useful for studying how simultaneous activation of two incretin pathways differs from selective GLP-1 receptor agonism.
Both molecules interact with the GLP-1 receptor, so they share part of the same biological signaling framework. Tirzepatide adds GIP receptor agonism.
GIP and GLP-1 are both incretin hormones involved in nutrient-responsive metabolic signaling, but their receptors are separate molecular targets. Activating them together creates a signaling profile that cannot be assumed to be identical to increasing GLP-1 receptor activity alone.
Research into tirzepatide has therefore examined whether the interaction between GIPR and GLP-1R contributes to biological effects beyond those produced by selective GLP-1 receptor agonists. Laboratory pharmacology suggests that tirzepatide’s behavior also depends on the balance and signaling characteristics of its activity at each receptor.
For researchers, this creates a useful distinction:
| Research Question | Semaglutide | Tirzepatide |
|---|---|---|
| Selective GLP-1R signaling | Strong research model | Present as part of dual activity |
| GIPR signaling | No primary agonist activity | Yes |
| Dual incretin signaling | No | Yes |
| Receptor-bias research | GLP-1-focused | Particularly relevant to GIPR/GLP-1R interaction |
| Comparing single vs. dual agonism | Reference GLP-1 model | Dual-receptor model |
For anyone researching semaglutide vs. tirzepatide, SURMOUNT-5 provides some of the strongest available comparative evidence.
Published in The New England Journal of Medicine in 2025, SURMOUNT-5 was a Phase 3b randomized, open-label, controlled trial involving 751 adults with obesity who did not have type 2 diabetes.
Participants were randomly assigned to receive the maximum tolerated study dose of either tirzepatide or semaglutide for 72 weeks.
| Outcome at 72 Weeks | Tirzepatide | Semaglutide |
|---|---|---|
| Mean body-weight change | -20.2% | -13.7% |
| Mean waist-circumference change | -18.4 cm | -13.0 cm |
| Trial population | Adults with obesity without type 2 diabetes | Adults with obesity without type 2 diabetes |
The between-group difference in body-weight change was statistically significant, with P<0.001. Participants assigned to tirzepatide were also more likely to reach the trial’s predefined thresholds for weight reductions of at least 10%, 15%, 20%, and 25%.
Gastrointestinal adverse events were the most common adverse events in both groups. Most were described as mild to moderate and occurred primarily during dose escalation.
SURMOUNT-5 supports a fairly specific conclusion:
Within this 72-week trial population and protocol, tirzepatide produced a greater mean reduction in body weight and waist circumference than semaglutide.
It does not establish that tirzepatide is superior for every research endpoint, biological pathway, disease population, or experimental application. That distinction is important because different endpoints require different experiments.
Researchers had directly compared tirzepatide and semaglutide even before SURMOUNT-5.
The SURPASS-2 trial, published in The New England Journal of Medicine in 2021, included 1,879 adults with type 2 diabetes. Its primary endpoint was change in glycated hemoglobin, or HbA1c, rather than obesity treatment alone.
At 40 weeks, mean HbA1c changes were:
| Study Group | Mean HbA1c Change |
|---|---|
| Tirzepatide 5 mg | -2.01 percentage points |
| Tirzepatide 10 mg | -2.24 percentage points |
| Tirzepatide 15 mg | -2.30 percentage points |
| Semaglutide 1 mg | -1.86 percentage points |
Tirzepatide met the trial criteria for both noninferiority and superiority to semaglutide for change in HbA1c.
Researchers also observed greater mean body-weight reductions in the tirzepatide groups. Compared with semaglutide, the estimated treatment differences were -1.9 kg, -3.6 kg, and -5.5 kg across the three tirzepatide dose groups.
There is an important limitation when interpreting this study alongside SURMOUNT-5: SURPASS-2 studied a different population and used semaglutide 1 mg rather than the higher semaglutide doses evaluated in obesity research.
The two trials answer different research questions.
Before direct head-to-head research was available, much of the discussion around tirzepatide vs. semaglutide came from separate clinical trials.
Those studies remain useful for establishing the independent evidence base for each compound.
The Phase 3 STEP 1 trial included 1,961 adults with overweight or obesity without diabetes and evaluated semaglutide against placebo over 68 weeks.
Researchers reported a mean body-weight change of -14.9% with semaglutide compared with -2.4% with placebo. More participants receiving semaglutide also reached weight-reduction thresholds of at least 5%, 10%, and 15%.
The Phase 3 SURMOUNT-1 trial included 2,539 adults with obesity or overweight and a weight-related complication who did not have diabetes.
At 72 weeks, mean changes in body weight were:
| Tirzepatide Study Group | Mean Body-Weight Change |
|---|---|
| 5 mg | -15.0% |
| 10 mg | -19.5% |
| 15 mg | -20.9% |
| Placebo | -3.1% |
The trial also reported improvements across several prespecified cardiometabolic measures.
These separate trials helped establish the research profile of each molecule, but STEP 1 and SURMOUNT-1 should not be treated as a true head-to-head comparison. Their populations, protocols, durations, doses, statistical methods, and study periods were different.
SURMOUNT-5 provides stronger comparative evidence because both compounds were studied within one randomized protocol.
Body weight and glucose regulation are only part of the available research. Semaglutide has particularly substantial cardiovascular-outcomes evidence.
The SELECT trial, published in The New England Journal of Medicine, enrolled 17,604 adults with preexisting cardiovascular disease and overweight or obesity who did not have diabetes.
A major cardiovascular event (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 6.5% of participants receiving semaglutide and 8.0% receiving placebo, corresponding to a hazard ratio of 0.80.
This research ultimately supported an additional FDA cardiovascular indication for Wegovy in 2024.
Tirzepatide also has cardiovascular-outcomes research. The large SURPASS-CVOT trial compared tirzepatide with dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Tirzepatide met the trial’s noninferiority criterion for major cardiovascular events; superiority over dulaglutide for the primary endpoint was not established.
Because SELECT and SURPASS-CVOT used different populations and comparators, they should not be used to declare one molecule superior to the other for cardiovascular outcomes.
There is considerable overlap, but the molecules should not be treated as pharmacologically identical.
In the major clinical trials, gastrointestinal events such as nausea, diarrhea, and vomiting were among the most frequently reported adverse events for both compounds. SURMOUNT-5 similarly reported gastrointestinal adverse events most frequently in both treatment groups.
Current FDA prescribing information for approved semaglutide and tirzepatide products also contains important warnings and precautions. Both Wegovy and Zepbound carry boxed warnings concerning thyroid C-cell tumors observed in rodent studies, although the relevance of those findings to humans has not been established.
For laboratory researchers, clinical adverse-event data can provide useful context, but they should not be confused with laboratory handling or experimental safety specifications for research compounds.
FDA-approved pharmaceutical products containing both molecules exist, but that does not mean every product containing semaglutide or tirzepatide is FDA-approved.
Semaglutide is the active ingredient in FDA-approved products including Ozempic and Wegovy. Tirzepatide is the active ingredient in products including Mounjaro and Zepbound. Each approved product has its own specific indications, formulation, manufacturing requirements, prescribing information, and regulatory status.
This distinction is particularly important in the research peptide market.
A compound supplied strictly for laboratory research is not interchangeable with an FDA-approved pharmaceutical product and should not be represented or used as one.
The comparison provides a practical model for studying how changes in receptor targeting affect biological signaling.
Semaglutide represents selective GLP-1 receptor agonism.
Tirzepatide represents combined GIP and GLP-1 receptor agonism.
Research involving these molecules can therefore contribute to work examining:
Foundational pharmacology studies are particularly valuable here. Semaglutide research shows how structural modification can extend the activity of a GLP-1 analogue, while tirzepatide research demonstrates how activity across two incretin receptors can be engineered into one peptide.
The answer depends on what is being measured and in which population.
For body-weight reduction in adults with obesity without type 2 diabetes, the published SURMOUNT-5 head-to-head trial found a greater mean reduction with tirzepatide than semaglutide at 72 weeks.
For glycemic control in adults with type 2 diabetes, SURPASS-2 also found greater reductions in HbA1c with the studied tirzepatide regimens than with the semaglutide regimen used in that trial.
Those findings should still be kept within their research context. They do not prove that tirzepatide is universally superior for every endpoint. Cardiovascular outcomes, molecular signaling, long-term safety, specific disease populations, and other research questions each require appropriate evidence.
That is a more scientifically useful conclusion than simply labeling one molecule “stronger.”
Semaglutide primarily targets GLP-1R. Tirzepatide targets both GIPR and GLP-1R.
That additional receptor activity gives tirzepatide a distinct pharmacological profile and makes the two molecules useful for comparing selective GLP-1 agonism with dual incretin agonism.
Clinical research has also moved beyond indirect comparisons. SURPASS-2 and SURMOUNT-5 directly compared the molecules under randomized trial conditions, with tirzepatide producing larger mean changes in the primary metabolic outcomes studied.
At the same time, semaglutide has a substantial independent evidence base, including STEP trials and the large cardiovascular SELECT trial. The scientific value of the comparison lies in examining how differences in receptor pharmacology translate into differences across specific experimental and clinical endpoints.
ReNu Wellness Peptides provides compounds strictly for laboratory and scientific research purposes. Products are not intended or approved for human or veterinary use.
Semaglutide is primarily a GLP-1 receptor agonist, whereas tirzepatide is a dual GIP and GLP-1 receptor agonist. The addition of GIP receptor activity is the main pharmacological difference.
Tirzepatide has GLP-1 receptor agonist activity, but calling it only a GLP-1 agonist leaves out an important part of its mechanism. It also activates the GIP receptor and is more accurately described as a dual GIP/GLP-1 receptor agonist.
Yes. SURPASS-2 directly compared the compounds in adults with type 2 diabetes, while SURMOUNT-5 directly compared them in adults with obesity without type 2 diabetes.
At 72 weeks, mean body-weight change was -20.2% with tirzepatide and -13.7% with semaglutide in the randomized Phase 3b trial. Tirzepatide also produced a greater mean reduction in waist circumference.
No. FDA-approved products containing semaglutide or tirzepatide are manufactured and regulated as approved pharmaceuticals for specific indications. Laboratory research compounds are a separate category and should not be treated as substitutes for approved drug products.
